The cannabinoid CB1 receptor antagonist AM251 does not modify methamphetamine reinstatement of responding

Sherin Y. Boctor, Joe L. Martinez, Wouter Koek, Charles P. France

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


Cannabinoid CB1 receptor antagonists can decrease methamphetamine self-administration. This study examined whether the CB1 receptor antagonist AM251 [N-(piperidin-1-yl)-5-(4-indophonyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide] modifies reinstatement in rats that previously self-administered methamphetamine. Rats (n = 10) self-administered methamphetamine (0.1 mg/kg/infusion) under a fixed ratio 2 schedule. Non-contingent methamphetamine (0.01-1.78 mg/kg, i.v.) yielded responding for saline (reinstatement) that was similar to responding for self-administered methamphetamine. AM251 (0.032-0.32, i.v.) did not affect methamphetamine-induced reinstatement but significantly attenuated {up triangle, open}9-tetrahydrocannabinol (2.0 mg/kg, i.p.)-induced hypothermia. These data fail to support a role for endogenous cannabinoids or cannabinoid CB1 receptors in reinstatement and, therefore, relapse to stimulant abuse.

Original languageEnglish (US)
Pages (from-to)39-43
Number of pages5
JournalEuropean Journal of Pharmacology
Issue number1
StatePublished - Sep 24 2007


  • (Rat)
  • AM251
  • Cannabinoid receptor
  • Methamphetamine
  • Reinstatement
  • Self-administration

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'The cannabinoid CB<sub>1</sub> receptor antagonist AM251 does not modify methamphetamine reinstatement of responding'. Together they form a unique fingerprint.

Cite this